Arkuda Therapeutics gets $64m booster to advance neurodegenerative treatment
Arkuda Therapeutics, a US-based biotechnology company, has raised $64 million in Series B financing. The new funding will help Arkuda Therapeutics boost the production of medicines that treat neurodegenerative diseases caused by the biological dysfunction of progranulin, a protein known to play a key role in lysosomal function and innate immunity in the brain. Arkuda […]